Sanara MedTech Inc 2026年季度报告

FORM 10-Q ☒QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026 or☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-39678 SANARA MEDTECH INC. (Exact name of Registrant as specified in its charter) Texas59-2219994(State or other jurisdiction of(I.R.S. Employerincorporation or organization)Identification No.) 1200 Summit Ave, Suite 414, Fort Worth, Texas 76102(Address of principal executive offices) (817) 529-2300(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days.☒Yes☐No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).☒Yes☐No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of August 7, 2026, 9,188,035 shares of the registrant’s common stock, $0.001 par value per share, were issued and outstanding. SANARA MEDTECH INC.Form 10-QQuarter Ended June 30, 2026 PagePart I - Financial Information3Item 1. Financial Statements3Consolidated Balance Sheets as of June 30, 2026 (Unaudited) and December 31, 20253Consolidated Statements of Operations (Unaudited) for the Three and Six Months Ended June 30, 2026 and 20254Consolidated Statements of Changes in Shareholders’ Equity (Unaudited) for the Three and Six Months Ended June 30, 2026and 20255Consolidated Statements of Cash Flows (Unaudited) for the Six Months Ended June 30, 2026 and 20256Notes to Unaudited Consolidated Financial Statements7Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations36Item 3. Quantitative and Qualitative Disclosures about Market Risk49Item 4. Controls and Procedures49Part II - Other Information50Item 1. Legal Proceedings50Item 1A. Risk Factors50Item 2. Unregistered Sales of Equity Securities and Use of Proceeds51Item 3. Defaults Upon Senior Securities51Item 4. Mine Safety Disclosures51Item 5. Other Information51Item 6. Exhibits52Signatures53Sanara, Sanara MedTech, our logo and our other trademarks or service marks appearing in this report are the property of SanaraMedTech Inc. Trade names, trademarks and service marks of other companies appearing in this report are the property of theirrespective owners. Solely for convenience, the trademarks, service marks and trade names included in this report are without the ®, ™ or other applicable symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extentunder applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names. Unless otherwise indicated, “Sanara MedTech,” “Sanara,” the “Company,” “our,” “us,” or “we,” refer to Sanara MedTech Inc. andits consolidated subsidiaries. PART I - Financial Information SANARA MEDTECH INC. AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETS SANARA MEDTECH INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) SANARA MEDTECH INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) SANARA MEDTECH INC. AND SUBSIDIARIESNOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS NOTE 1 — NATURE OF BUSINESS AND BACKGROUND Sanara MedTech Inc. (together with its wholly owned and majority owned subsidiaries on a consolidated basis, the “Company”) is amedical technology company focused on developing and commercializing transformative technologies to improve clinical outcomesand reduce healthcare expenditures in the surgical market. Each of the Company’s products are designed to achieve the Company’sgoal of providing better clinical outcomes at a lower overall cost for healthcare systems. The Co